Medication info

Pregabalin Capsule 75mg (Pregabalin)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Seongwon Adcock Pharmaceuticals Co., Ltd.
Appearance
A hard capsule with a brown upper half and a white lower half containing white powder
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Expired

MFDS item code 201902108 · Approved 2019.04.05

This product's status changed to Expired on 2024.04.05. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this drug as pregabalin orally in 2 divided doses, with or without food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5. Patients with Renal Impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4. Discontinuation). 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over an interval of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is excreted primarily by the kidneys unchanged. Since clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after every 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = divide the total daily dose into 3 doses BID = divide the total daily dose into 2 doses QD = administer once daily a: The total daily dose (mg/day) should be divided as specified under Administration method. b: An additional dose refers to a dose administered once as a supplement. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
7. Pediatric and adolescent patients There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12-17 years; use is not recommended.

Ingredients

Manufacturer
Seongwon Adcock Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures with secondary generalization
  • partial seizures without secondary generalization
  • fibromyalgia
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment in patients with epilepsy for partial seizures, effective with or without secondary generalized symptoms. It is applied in the treatment of fibromyalgia and helps improve symptoms. It is used to treat major conditions like neuropathic pain, epilepsy, and fibromyalgia.

How to take

Adult dose

Administer the total daily dose of this drug as pregabalin orally in 2 divided doses, with or without food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5. Patients with Renal Impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4. Discontinuation). 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over an interval of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is excreted primarily by the kidneys unchanged. Since clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after every 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = divide the total daily dose into 3 doses BID = divide the total daily dose into 2 doses QD = administer once daily a: The total daily dose (mg/day) should be divided as specified under Administration method. b: An additional dose refers to a dose administered once as a supplement. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

7. Pediatric and adolescent patients There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12-17 years; use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behavior; therefore, if symptoms of depression, mood changes, or abnormal behavior occur during treatment, consult a physician immediately. This medication should not be administered to patients with hypersensitivity to its components or certain genetic metabolic disorders. Diabetic patients may experience weight gain after taking this drug, which may require adjustment of their blood glucose control medications. If symptoms of angioedema, such as swelling around the face or mouth, occur due to hypersensitivity, ingestion must be stopped immediately. Elderly patients may experience increased dizziness or drowsiness when taking this medication, so caution is advised until they become accustomed to its effects. This drug may cause blurred vision or changes in eyesight; consult a physician if these symptoms occur. Withdrawal symptoms such as insomnia, headache, and anxiety may occur upon discontinuation; thus, it is advised to taper off according to medical personnel's instructions. Due to the risk of drug abuse, patients with a history of substance abuse should be monitored more carefully. Patients with impaired kidney function may require dosage adjustments of this medication. Patients with heart failure or cardiovascular diseases should use this drug cautiously. When taken with opioid analgesics, there is a risk of central nervous system depression, so caution is advised. Patients with respiratory diseases, renal impairment, or the elderly may require dosage adjustments due to the risk of severe respiratory depression. This medication can cause dizziness and drowsiness, and thus driving or operating hazardous machinery should be avoided during treatment. This medication is primarily excreted through urine, and while pharmacokinetic interactions with other drugs are minimal, caution is required if taken together with central nervous system depressants. During pregnancy, there is a potential risk to the fetus, so it should only be administered when necessary, and fertile women should use effective contraception. This medication is excreted in breast milk, so careful consideration is needed regarding breastfeeding and administration of the drug. In case of overdose, symptoms such as confusion, drowsiness, or depression may occur, and treatments such as dialysis may be necessary if required. Keep out of reach of children, and do not transfer to another container.

Side effects

  • Suicidal impulses
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 175 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • depression
  • pain
  • seizures
  • hyperhidrosis
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • spatial disorientation
  • irritability
  • elation
  • decreased libido
  • depersonalization
  • sexual dysesthesia
  • agitation
  • mood swings
  • emotional blunting
  • emotional elation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • reflex decrease
  • movement disorders
  • psychomotor agitation
  • position-related dizziness
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing difficulties
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • nasal bleeding
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tightness
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • abnormal sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • elevated alanine aminotransferase
  • increased serum creatine phosphokinase
  • elevated aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased blood potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue swelling
  • itching
  • urinary retention
  • gynecomastia
  • fatigue
  • delirium
  • paralysis
  • mood disorders
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • worsening of seizures
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • blood in stool

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture, preferably in a cool place between 15 and 30 degrees Celsius. Storing it this way can maintain the drug's effectiveness for a long time.

Appearance and packaging

Appearance

A hard capsule with a brown upper half and a white lower half containing white powder

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.